Sage gets U.S. approval for first postpartum depression therapy

The U.S. Food and Drug Administration on Tuesday Sage Therapeutics Inc's drug for severe postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.